Showing results (81-90 of 97) with videos related to

Sort By:
Pageof 10
Arthritis Care & Research|February 17, 2018
High Adherence to System-Level Performance Measures for Rheumatoid Arthritis in a National Early Arthritis Cohort Over Eight YearsClaire E H Barber, Orit Schieir, Diane Lacaille, et al.
Expert Opinion on Investigational Drugs|May 26, 2023
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I studyKyung-Sang Yu, Byungwook Kim, Dongseong Shin, et al.
Chest|May 12, 2009
Minor salivary gland biopsy to detect primary Sjogren syndrome in patients with interstitial lung diseaseAryeh Fischer, Jeffrey J Swigris, Roland M du Bois, et al.
Arthritis Research & Therapy|February 6, 2021
Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized studyJonathan Kay, Janusz Jaworski, Rafal Wojciechowski, et al.
Arthritis Care & Research|June 28, 2012
Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activityJeffrey R Curtis, Annette H van der Helm-van Mil, Rachel Knevel, et al.
RMD Open|October 18, 2024
Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47Josef S Smolen, Jakub Trefler, Artur Racewicz, et al.
Arthritis and Rheumatism|January 26, 2013
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic studyDésirée van der Heijde, Yoshiya Tanaka, Roy Fleischmann, et al.
Rheumatology (Oxford, England)|June 18, 2021
Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritisDaniel E Furst, Janusz Jaworski, Rafal Wojciechowski, et al.
The Journal of Rheumatology|April 3, 2008
Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)Christian E Antoni, Arthur Kavanaugh, Désirée van der Heijde, et al.
Clinical and Translational Science|January 27, 2021
Pharmacokinetic equivalence of CT-P17 to high-concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjectsKyung-Sang Yu, In-Jin Jang, Hyeong-Seok Lim, et al.
Pageof 10